医学
内科学
中期分析
危险系数
临床终点
安慰剂
培美曲塞
化疗
肿瘤科
肺癌
无进展生存期
非小细胞肺癌
随机对照试验
外科
置信区间
病理
顺铂
替代医学
A549电池
作者
Caicun Zhou,Ziping Wang,Meili Sun,Lejie Cao,Zhiyong Ma,Rong Wu,Yan Yu,Wenxiu Yao,Si Sun,Jianhua Chen,Wu Zhuang,Jiuwei Cui,Xueqin Chen,You Lü,Hong Shen,Chunhong Hu,Jiwei Liu,Yunpeng Liu,Mengzhao Wang,Xingya Li
出处
期刊:Nature cancer
[Nature Portfolio]
日期:2023-06-15
卷期号:4 (6): 860-871
被引量:46
标识
DOI:10.1038/s43018-023-00578-z
摘要
Abstract In the primary analysis of the GEMSTONE-302 trial, sugemalimab plus platinum-based chemotherapy conferred significantly longer progression-free survival (PFS) versus placebo in patients with previously untreated metastatic non-small-cell lung cancer (NSCLC) with no known driver oncogene alterations. Here we report data from a protocol pre-specified interim overall survival (OS) analysis of that trial. In this randomised, double-blind, phase III trial (NCT03789604), adult patients with systemic-treatment-naïve stage IV NSCLC and no known driver oncogene alterations were randomised 2:1 to receive sugemalimab (1200 mg, intravenously) or placebo plus platinum-based chemotherapy every 3 weeks for up to four cycles, followed by maintenance therapy with intravenous sugemalimab or placebo plus pemetrexed (non-squamous NSCLC) or sugemalimab or placebo (squamous NSCLC). Placebo-treated patients could cross over to receive sugemalimab monotherapy upon disease progression. As of 22 November 2021 [median follow-up, 25.4 months (sugemalimab) vs 24.9 months (placebo)], median OS was 25.4 months [95% confidence interval (CI) 20.1-not reached] and 16.9 months (95% CI 12.8–20.7) for the sugemalimab and placebo groups, respectively [hazard ratio (HR) 0.65, 95% CI 0.50–0.84; P = 0.0008]. Median investigator-assessed PFS was 9.0 months (95% CI 7.4–10.9) and 4.9 months (95% CI 4.8–5.2), respectively (HR 0.49, 95% CI 0.40–0.61; P < 0.0001). The OS and PFS benefit with sugemalimab was maintained regardless of histology types and programmed death-ligand 1 (PD-L1) expression. Sugemalimab-treated patients had a significantly higher objective response rate (ORR) versus placebo (63.4% versus 40.3%; P < 0.0001) with a longer median duration of response [9.9 months (95% CI 8.6–13.2) versus 4.4 months (95% CI 3.5–6.1)]. There were no new safety signals. Sugemalimab plus chemotherapy conferred a statistically significant and clinically meaningful improvement in OS and PFS regardless of PD-L1 expression and histology types, supporting sugemalimab as a new first-line treatment option for metastatic NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI